OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
5,00 $
arrow_upward
+1,60%(+0,079) 1D
16 қаз., 13:48:40 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for OPHLY...
Open
5,05 $
High
5,07 $
Low
4,98 $
Mkt. cap
1,20 трлн
Avg. vol.
62,80 мың
Volume
13,78 мың
52-wk high
5,75 $
52-wk low
3,82 $
Beta
0,21
Shares outstanding
1,50 млрд
No. of employees
4 мың
Open
5,05 $
High
5,07 $
Low
4,98 $
Mkt. cap
1,20 трлн
Avg. vol.
62,80 мың
Volume
13,78 мың
52-wk high
5,75 $
52-wk low
3,82 $
Beta
0,21
Shares outstanding
1,50 млрд
No. of employees
4 мың
News stories
From web sources and news partners
Simply Wall Street
·
36 минут бұрын
Walmart (WMT) Adds Premium Wellness Products To More Than 2,300 Stores
Moomoo
·
1 сағат бұрын
Dow Jones Top Company Headlines at 1 PM ET: Tesla's New Roadster Takes Flight After Nearly a Decade of Delays | CoreWeave ...
MarketBeat
·
15 минут бұрын
Peoples Financial Services Corp. (NASDAQ:PFIS) Stock Short Interest Report for September
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Employees4,21 мың
Founded1717
HeadquartersОсака, Osaka, Жапония
SectorPharmaceutical industry
Websiteono-pharma.com